Reduction of Tumor Growth with RNA-Targeting Treatment of the NAB2–STAT6 Fusion Transcript in Solitary Fibrous Tumor Models

Anti-angiogenic

[1]  Xuebing Wu,et al.  Collateral activity of the CRISPR/RfxCas13d system in human cells , 2023, Communications Biology.

[2]  Lili Cao,et al.  The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model , 2023, Genome Biology.

[3]  A. Kater,et al.  JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL , 2022, Molecular oncology.

[4]  B. Ghanim,et al.  Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib , 2022, Cancers.

[5]  R. Maestro,et al.  ISG15 as a prognostic biomarker in solitary fibrous tumour , 2022, Cellular and Molecular Life Sciences.

[6]  Shawn Hoon,et al.  Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans , 2022, Nature Medicine.

[7]  T. Tsukahara,et al.  Development of Therapeutic RNA Manipulation for Muscular Dystrophy , 2022, Frontiers in Genome Editing.

[8]  L. Roberts,et al.  RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? , 2022, Frontiers in Oncology.

[9]  M. Emdin,et al.  RNA-targeting and gene editing therapies for transthyretin amyloidosis , 2022, Nature Reviews Cardiology.

[10]  S. Ro,et al.  Current Advances in RNA Therapeutics for Human Diseases , 2022, International journal of molecular sciences.

[11]  J. Blay,et al.  Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond , 2022, Cancers.

[12]  S. Sathyanarayanan,et al.  Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity , 2022, Science advances.

[13]  Zikang Wang,et al.  High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects , 2021, bioRxiv.

[14]  W. Tarn,et al.  Antisense Oligonucleotide-Based Therapy of Viral Infections , 2021, Pharmaceutics.

[15]  Andrew J Want,et al.  Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm , 2021, EBioMedicine.

[16]  A. Abulrob,et al.  Antisense oligonucleotides: absorption, distribution, metabolism, and excretion , 2021, Expert opinion on drug metabolism & toxicology.

[17]  R. Langer,et al.  Nucleic Acid Delivery for Therapeutic Applications. , 2021, Advanced drug delivery reviews.

[18]  D. Agostini-Vulaj,et al.  Solitary fibrous tumor presenting as a colonic polyp: Report of a case and literature review , 2021 .

[19]  A. Feigin,et al.  Emerging therapeutics in Huntington’s disease , 2021, Expert opinion on emerging drugs.

[20]  J. W. Pruitt,et al.  The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy. , 2021, Orthopedic reviews.

[21]  S. Crooke,et al.  Site-specific Incorporation of 2',5'-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides. , 2021, ACS medicinal chemistry letters.

[22]  B. Davidson,et al.  Gene therapy for ALS: A review , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  R. Eils,et al.  Gene expression in Solitary Fibrous Tumors (SFTs) correlates with anatomical localization and NAB2-STAT6 gene fusion variants. , 2021, The American journal of pathology.

[24]  Anushya Muruganujan,et al.  PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API , 2020, Nucleic Acids Res..

[25]  Chance M. Nowak,et al.  Uncoupling gene expression noise along the central dogma using genome engineered human cell lines , 2020, Nucleic acids research.

[26]  P. Rocchi,et al.  Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting , 2020, Molecular Cell.

[27]  Z. Ryoo,et al.  NAB2-STAT6 fusion protein mediates cell proliferation and oncogenic progression via EGR-1 regulation. , 2020, Biochemical and biophysical research communications.

[28]  Neville E. Sanjana,et al.  Massively parallel Cas13 screens reveal principles for guide RNA design , 2020, Nature Biotechnology.

[29]  Ansar Karimian,et al.  CRISPR/Cas9 technology as a potent molecular tool for gene therapy , 2019, Journal of cellular physiology.

[30]  Chance M. Nowak,et al.  p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. , 2019, Cell reports.

[31]  Christopher E. Hart,et al.  Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index , 2019, Nature Biotechnology.

[32]  Jiansong Ji,et al.  CRISPR-Cas9 for cancer therapy: Opportunities and challenges. , 2019, Cancer letters.

[33]  V. Razban,et al.  Creating cell and animal models of human disease by genome editing using CRISPR/Cas9 , 2019, The journal of gene medicine.

[34]  Chance M. Nowak,et al.  CRISPR-Based Editing Reveals Edge-Specific Effects in Biological Networks. , 2018, The CRISPR journal.

[35]  S. Konermann,et al.  Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors , 2018, Cell.

[36]  Li Ding,et al.  Driver Fusions and Their Implications in the Development and Treatment of Human Cancers , 2018, Cell reports.

[37]  G. Storm,et al.  Targeting the Stat6 pathway in tumor‐associated macrophages reduces tumor growth and metastatic niche formation in breast cancer , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  T. Gant,et al.  Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs , 2017, Molecular therapy. Nucleic acids.

[39]  T. Tominaga,et al.  Intraspinal dissemination of intracranial hemangiopericytoma: Case report and literature review , 2016, Surgical neurology international.

[40]  Chance M. Nowak,et al.  Guide RNA engineering for versatile Cas9 functionality , 2016, Nucleic acids research.

[41]  Jeffrey T Leek,et al.  Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown , 2016, Nature Protocols.

[42]  A. Bellizzi,et al.  The NAB2-STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing. , 2016, Cancer genetics.

[43]  S. T. Bjorkman,et al.  Standard loading controls are not reliable for Western blot quantification across brain development or in pathological conditions , 2016, Electrophoresis.

[44]  M. White,et al.  Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions , 2016, PloS one.

[45]  Yi Li,et al.  CRISPR-based self-cleaving mechanism for controllable gene delivery in human cells , 2014, Nucleic acids research.

[46]  Mazhar Adli,et al.  Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease , 2014, Nature Biotechnology.

[47]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[48]  A. Jochemsen,et al.  p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway , 2013, Cell Death and Differentiation.

[49]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[50]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[51]  Daniel Auclair,et al.  Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors , 2013, Nature Genetics.

[52]  K. Pienta,et al.  Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing , 2013, Nature Genetics.

[53]  A. Maity,et al.  Molecular Neuroscience Review Article , 2011 .

[54]  C. Figdor,et al.  Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. , 2011, The Journal of clinical investigation.

[55]  Fermín Sánchez de Medina,et al.  Reversible Ponceau staining as a loading control alternative to actin in Western blots. , 2010, Analytical biochemistry.

[56]  Yun Wang,et al.  Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. , 2008, Virology.

[57]  M. Herlyn,et al.  The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. , 2007, Genes & development.

[58]  J. Rao,et al.  Solitary Fibrous Tumor , 2005, Acta Cytologica.

[59]  D. Kondziolka,et al.  Radiosurgery for Treatment of Recurrent Intracranial Hemangiopericytomas , 2002, Neurosurgery.

[60]  B. Scheithauer,et al.  Management of recurrent meningeal hemangiopericytoma , 1998, Cancer.